Key result
Spironolactone reduces major cardiovascular events in machine learning-identified responders but not non-responders.
Why the study?
It was unclear whether a specific subset of patients with HFpEF benefits from spironolactone therapy.
Does spironolactone reduce the composite of cardiovascular death, aborted cardiac arrest, or heart failure hospitalization in a machine-learning identified responder subset of patients with HFpEF?
RCT (n=947)
Does spironolactone reduce the composite of cardiovascular death, aborted cardiac arrest, or heart failure hospitalization in a machine-learning identified responder subset of patients with HFpEF?
p-value: p=0.008
Machine learning algorithms using readily available clinical variables can identify a specific phenotype of HFpEF patients who derive significant clinical benefit from spironolactone therapy.
May support targeted spironolactone use via ML phenotyping in HFpEF; leaves open prospective validation before practice change.
BACKGROUND: Whether there is a subset of patients with heart failure with preserved ejection fraction (HFpEF) that benefit from spironolactone therapy is unclear. We applied a machine learning approach to identify responders and non-responders to spironolactone among patients with HFpEF in two large randomized clinical trials. METHODS: Using a reiterative cluster allocating permutation approach, patients from the derivation cohort (Aldo-DHF) were identified according to their treatment response to spironolactone with respect to improvement in E/e'. Heterogenous features of response ('responders' and 'non-responders') were characterized by an extreme gradient boosting (XGBoost) algorithm. XGBoost was used to predict treatment response in the validation cohort (TOPCAT). The primary endpoint of the validation cohort was a combined endpoint of cardiovascular mortality, aborted cardiac arrest, or heart failure hospitalization. Patients with missing variables for the XGboost model were excluded from the validation analysis. FINDINGS: Out of 422 patients from the derivation cohort, reiterative cluster allocating permutation identified 159 patients (38%) as spironolactone responders, in whom E/e' significantly improved (p = 0.005). Within the validation cohort (n = 525) spironolactone treatment significantly reduced the occurrence of the primary outcome among responders (n = 185, p log rank = 0.008), but not among patients in the non-responder group (n = 340, p log rank = 0.52). INTERPRETATION: Machine learning approaches might aid in identifying HFpEF patients who are likely to show a favorable therapeutic response to spironolactone. FUNDING: See Acknowledgements section at the end of the manuscript.
No takes yet. Share an insight, caveat, or question.
Kresoja et al. (2023) conducted an RCT in Heart failure with preserved ejection fraction (HFpEF) (n=947). Spironolactone was evaluated on Combined endpoint of cardiovascular mortality, aborted cardiac arrest, or heart failure hospitalization (p=0.008). Spironolactone significantly reduced cardiovascular mortality, aborted cardiac arrest, or heart failure hospitalization among machine learning-identified responders (p=0.008) but not non-responders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: